Expand
Ramipril lowers blood pressure in various models of hypertension and improves states of acute cardiac failure mainly by suppression of angiotensin II formation
Angiotensin II is a potent vasoconstrictor and stimulates sympathetic stimulation, renal hypertension, and synthesis of aldosterone
Ramipril is an angiotensin-converting enzyme (ACE) inhibitor and is utilized for multiple indications, including hypertension and prevention of heart failure progression following a myocardial infarction (MI)
Ian S
Ramipril is a prodrug that undergoes de-esterification in the liver to form ramiprilat, its active metabolite
Meisel, A
5 mg ramipril orally, 2
Peak plasma concentrations of ramiprilat attained within 2-4 hours after oral dose
Abstract Ramipril is a potent orally active converting enzyme inhibitor
8137599 [ View in PubMed ] Abstract Ramipril is a long-acting nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor introduced for clinical use about a decade ago
The ability of aldosterone to cause sodium and water The pharmacokinetics and pharmacodynamics of single oral doses of 5 mg ramipril and 6 mg piretanide administered separately and in combination were determined in a single blind, randomised, 3-period cross-over study in 24 healthy male volunteers
96 ng/ml, respectively) as The angiotensin converting enzyme inhibitor ramiprilat was evaluated in horses after ramipril administration
1007/BF00679779
To investigate the pharmacokinetics and pharmacodynamics of a new angiotensin converting enzyme (ACE) inhibitor, ramipril (HOE 498), in patients with cardiac insufficiency (NYHA III-IV), we performed an open trial with a follow-up of 10 days
5 mg q12hr depending on clinical response and tolerability
The pharmacokinetics of Ramipril is an angiotensin converting enzyme (ACE) inhibitor
Ramipril is an ACE inhibitor which prevents the formation of angiotensin II from angiotensin I and exhibits pharmacologic effects that are similar to captopril
Ramipril was rapidly absorbed and reached a peak concentration after 1-2 h
1
Ramipril / pharmacokinetics Ramipril / pharmacology Ramipril / therapeutic use* Ramipril is a long-acting, lipophylic angiotensin converting enzyme inhibitor, its principle action is to inhibit the conversion of angiotensin I to the active angiotensin II
Peak plasma concentrations of ramiprilat occurred within 2-3 hours
RAM, HCTZ and the internal standards (RAM-D5, HCTZ-13C, D2) were ex-tracted from human plasma by direct protein precipitation
The figure schematically illustrates the events in three different tissues (typical "tissue", the liver Ramipril capsules are an angiotensin converting enzyme (ACE) inhibitor indicated for the treatment of hypertension, to lower blood pressure
Pharmacokinetics
An indication of possible toxic ranges based on the analysis of real samples with high ramiprilat concentrations is provided, from about 600 ng/mL to at least 3500 ng/, which can be applied in the forensic practice as a reference for future cases
The area under the plasma level-time curves of ramipril and ramiprilate in IRF were greater than those in NRF
Stephen Davis, in xPharm: The Comprehensive Pharmacology Reference, 2007
Although the overall effect of the cytochrome P450 (P450) family of drug-metabolizing enzymes in this capacity cannot be understated, advancements in the field of non-P450-mediated Ramipril
The initial decrease in blood pressure occurs within 2 hours of The pharmacokinetics of ramipril and its active metabolite, ramiprilat, was determined in cats following single and repeated oral doses of ramipril (Vasotop tablets) (once daily for 9 days) at dose rates of 0
These agents are in various classes and categories of medication
Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII)
Upon taking the medication, the maximum plasma concentration in the therapeutic window is typically
Ramipril is a prodrug that undergoes de-esterification in the liver to form ramiprilat, its active metabolite
Ramipril inhibited plasma ACE ac- pril diacid metabolite and the drug-induced plasma tivity, an effect that peaked at 3 to 4 hours and per- ACE activity
8 ng/ml after 1
Following oral administration, peak plasma concentrations of ramipril usually attained within 1 hour
Abstract Ramipril is a potent orally active converting enzyme inhibitor
8137599 [ View in PubMed ] Abstract Ramipril is a long-acting nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor introduced for clinical use about a decade ago
The objectives of the present study were: (1) to establish the serum concentration–time profile for ramipril, and its active metabolite ramiprilat after IV
There are few reports on the pharmacokinetics of ramipril after multiple-dose administration of Clinical Pharmacokinetics of Ramipril
Ramipril is a prodrug that undergoes de-esterification in the liver to form Ramipril and ramiprilat inhibit ACE in human subjects and animals
25, 0
Like enalapril it is a prodrug, which is hydrolysed after absorption to form the active metabolite ramiprilat which has a long elimination half-life, permitting once daily administration
8 ng/ml, and
8 Ramipril capsules are an angiotensin converting enzyme (ACE) inhibitor indicated for the treatment of hypertension, to lower blood pressure
Ramipril Pharmacokinetics Absorption Bioavailability
All patients had a T-drain inserted to permit bile collection; all gave their informed consent to participate in the trial
ARBs are less associated with angioedema than ACE
It can also be used as a preventative medication in patients over 55 years old to reduce the risk of having a heart attack, stroke or cardiovascular death in patients shown to be at
NSAIDs can impair the hypotensive effects of ACE-I by blocking bradykinin-mediated vasodilation Lisinopril is classified as an angiotensin-converting enzyme inhibitor and has been available for nearly three decades
Human Pharmacokinetics
These terms were first presented together in English by Nelson in 1961, rephrasing resorption, distribution, consumption and elimination used by Teorell in 1937 [Nelson, 1961; Teorell, 1937]
The ability of aldosterone to cause sodium and water ACE inhibitors are medications used to treat and manage hypertension, which is a significant risk factor for coronary disease, heart failure, stroke, and a host of other cardiovascular conditions
The angiotensin converting enzyme inhibitor ramiprilat was evaluated in horses after ramipril administration
25 mg PO qDay; may increase to 1